Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations
JAMA
.
2021 Jan 5;325(1):36-38.
doi: 10.1001/jama.2020.23371.
Authors
Heather A Parsons
1
,
Harold J Burstein
1
Affiliation
1
Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
PMID:
33300953
DOI:
10.1001/jama.2020.23371
No abstract available
Publication types
Editorial
Comment
MeSH terms
Breast Neoplasms* / drug therapy
Capecitabine / therapeutic use
Chemotherapy, Adjuvant
Disease-Free Survival
Humans
Maintenance
Triple Negative Breast Neoplasms* / drug therapy
Substances
Capecitabine
Grants and funding
L30 CA188997/CA/NCI NIH HHS/United States